Woolfson Eye Institute
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Woolfson Eye Institute sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Woolfson Eye Institute: 2 sponsored US clinical trials, 2 recruiting.
Woolfson Eye Institute sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Forme Fruste Keratoconus (FFK), with 2 trials.
Mid-pack sponsor footprint
Woolfson Eye Institute is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
NCT07124910
Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
NCT07135167
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Where Woolfson Eye Institute enrollment is open (later-stage tilt)
2 recruiting of 2 indexed (100% open).
Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Forme Fruste Keratoconus (FFK) (2 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Woolfson Eye Institute: open-pipeline peers nationwide
Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Woolfson Eye Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Woolfson Eye Institute page
2 registered trials is a research-attention snapshot, not an endorsement of Woolfson Eye Institute or any single study.
- 2 of Woolfson Eye Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Forme Fruste Keratoconus (FFK) is the condition Woolfson Eye Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Forme Fruste Keratoconus (FFK) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Woolfson Eye Institute pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.